Fig. 2From: Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort studyFlow chart for sample selection. DPP-4i dipeptidyl peptidase-4 inhibitors, DM diabetes mellitus, SGLT-2i sodium glucose co-transporter 2 inhibitor, GLP-1 glucagon‐like peptide 1, MACE major adverse cardiovascular eventBack to article page